IL244506B - A sodium channel modulator for the treatment of pain and diabetes - Google Patents
A sodium channel modulator for the treatment of pain and diabetesInfo
- Publication number
- IL244506B IL244506B IL244506A IL24450616A IL244506B IL 244506 B IL244506 B IL 244506B IL 244506 A IL244506 A IL 244506A IL 24450616 A IL24450616 A IL 24450616A IL 244506 B IL244506 B IL 244506B
- Authority
- IL
- Israel
- Prior art keywords
- diabetes
- pain
- treatment
- sodium channel
- channel modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361876046P | 2013-09-10 | 2013-09-10 | |
| PCT/US2014/054764 WO2015038533A2 (en) | 2013-09-10 | 2014-09-09 | Sodium channel modulators for the treatment of pain and diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL244506A0 IL244506A0 (en) | 2016-04-21 |
| IL244506B true IL244506B (en) | 2020-02-27 |
Family
ID=52666496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL244506A IL244506B (en) | 2013-09-10 | 2016-03-09 | A sodium channel modulator for the treatment of pain and diabetes |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20160221974A1 (OSRAM) |
| EP (1) | EP3043787B1 (OSRAM) |
| JP (1) | JP6445565B2 (OSRAM) |
| KR (1) | KR20160054570A (OSRAM) |
| CN (1) | CN105611923B (OSRAM) |
| AU (1) | AU2014318979B2 (OSRAM) |
| BR (1) | BR112016005271A2 (OSRAM) |
| CA (1) | CA2922851C (OSRAM) |
| ES (1) | ES2687598T3 (OSRAM) |
| IL (1) | IL244506B (OSRAM) |
| MX (1) | MX2016002881A (OSRAM) |
| MY (1) | MY181928A (OSRAM) |
| PH (1) | PH12016500296A1 (OSRAM) |
| RU (1) | RU2016113156A (OSRAM) |
| SG (2) | SG10201805552PA (OSRAM) |
| UA (1) | UA120353C2 (OSRAM) |
| WO (1) | WO2015038533A2 (OSRAM) |
| ZA (1) | ZA201702410B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179781B2 (en) * | 2013-03-15 | 2019-01-15 | Chromocell Corporation | Sodium channel modulators for the treatment of pain |
| EP3043787B1 (en) | 2013-09-10 | 2018-09-05 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
| JP2017527573A (ja) * | 2014-09-09 | 2017-09-21 | クロモセル コーポレーション | 糖尿病の治療用の選択的ＮａＶ１．７阻害剤 |
| CN108699015A (zh) | 2015-12-18 | 2018-10-23 | 默沙东公司 | 对电压门控性钠通道具有选择性活性的羟基烷基胺-和羟基环烷基胺-取代的二胺-芳基磺胺化合物 |
| HUE071358T2 (hu) | 2016-05-20 | 2025-08-28 | Xenon Pharmaceuticals Inc | Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk |
| CN106084535A (zh) * | 2016-06-02 | 2016-11-09 | 扬州兰都塑料科技有限公司 | 一种耐刮擦的电力电缆的制备方法 |
| CN105924843A (zh) * | 2016-06-02 | 2016-09-07 | 扬州兰都塑料科技有限公司 | 一种耐刮擦的电力电缆 |
| CN105924670A (zh) * | 2016-06-02 | 2016-09-07 | 扬州兰都塑料科技有限公司 | 一种电力电缆用耐磨剂 |
| JP7022751B2 (ja) | 2016-12-09 | 2022-02-18 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 |
| CN106892845B (zh) * | 2017-02-28 | 2018-10-30 | 四川同晟生物医药有限公司 | 一种2,4-二氨基丁酸衍生物及其制备方法 |
| WO2019200369A1 (en) * | 2018-04-13 | 2019-10-17 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage |
| WO2019217822A1 (en) * | 2018-05-11 | 2019-11-14 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions |
| SG11202011862PA (en) | 2018-06-13 | 2020-12-30 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
| CN112638898B (zh) | 2018-08-31 | 2024-04-09 | 泽农医药公司 | 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 |
| CN113527281B (zh) * | 2020-04-20 | 2023-12-22 | 昆山彭济凯丰生物科技有限公司 | 杂环化合物及其制备方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| KR20030082982A (ko) * | 2001-03-14 | 2003-10-23 | 그뤼넨탈 게엠베하 | 치환된 피라졸로피리미딘 및 티아졸로피리미딘 |
| US7659082B2 (en) | 2002-02-19 | 2010-02-09 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
| CA2488642C (en) | 2002-06-27 | 2011-09-06 | Dharma Rao Polisetti | Aryl carbonyl derivatives as glucokinase activators |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| US7449477B2 (en) | 2003-11-25 | 2008-11-11 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) |
| EP1751136B1 (en) | 2004-05-07 | 2014-07-02 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| EP1802580A2 (en) * | 2004-07-23 | 2007-07-04 | Pfizer, Inc. | Pyridine derivatives |
| MX2007004862A (es) | 2004-10-29 | 2007-05-09 | Astrazeneca Ab | Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias. |
| CN101336229B (zh) * | 2005-12-23 | 2012-06-13 | 西兰岛药物有限公司 | 改性的拟赖氨酸化合物 |
| WO2008097991A1 (en) * | 2007-02-05 | 2008-08-14 | Xenon Pharmaceuticals Inc. | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
| US8124610B2 (en) | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
| JP5463285B2 (ja) | 2007-07-13 | 2014-04-09 | アイカジェン， インコーポレイテッド | ナトリウムチャネル阻害物質 |
| HRP20150355T1 (hr) | 2009-01-12 | 2015-06-19 | Pfizer Limited | Sulfonamidni derivati |
| JP5685203B2 (ja) | 2009-05-29 | 2015-03-18 | ラクオリア創薬株式会社 | カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体 |
| EP2560636A4 (en) | 2010-04-23 | 2013-11-27 | Kineta Inc | ANTIVIRAL CONNECTIONS |
| EP2590957B1 (en) | 2010-07-09 | 2014-11-12 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| CA2804593C (en) * | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
| US9145407B2 (en) | 2010-07-09 | 2015-09-29 | Pfizer Limited | Sulfonamide compounds |
| WO2012007883A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| EA201370161A1 (ru) | 2011-01-18 | 2013-12-30 | Амген Инк. | НОКАУТНЫЕ ПО Na1.7 МЫШИ И ИХ ПРИМЕНЕНИЕ |
| TW201837023A (zh) * | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| JP2014521749A (ja) | 2011-08-17 | 2014-08-28 | アムジエン・インコーポレーテツド | ヘテロアリールナトリウムチャネル阻害剤 |
| US20140221286A1 (en) | 2011-09-21 | 2014-08-07 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| WO2014078479A2 (en) | 2012-11-14 | 2014-05-22 | The Board Of Regents Of The University Of Texas System | INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT) |
| US10179781B2 (en) * | 2013-03-15 | 2019-01-15 | Chromocell Corporation | Sodium channel modulators for the treatment of pain |
| SI3417851T1 (sl) | 2013-09-09 | 2020-11-30 | Peloton Therapeutics, Inc. | Aril etri in njihova uporaba |
| EP3043787B1 (en) | 2013-09-10 | 2018-09-05 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
| JP2017527573A (ja) * | 2014-09-09 | 2017-09-21 | クロモセル コーポレーション | 糖尿病の治療用の選択的ＮａＶ１．７阻害剤 |
-
2014
- 2014-09-09 EP EP14843353.5A patent/EP3043787B1/en active Active
- 2014-09-09 KR KR1020167009294A patent/KR20160054570A/ko not_active Ceased
- 2014-09-09 SG SG10201805552PA patent/SG10201805552PA/en unknown
- 2014-09-09 UA UAA201603676A patent/UA120353C2/uk unknown
- 2014-09-09 CA CA2922851A patent/CA2922851C/en active Active
- 2014-09-09 MX MX2016002881A patent/MX2016002881A/es active IP Right Grant
- 2014-09-09 WO PCT/US2014/054764 patent/WO2015038533A2/en not_active Ceased
- 2014-09-09 RU RU2016113156A patent/RU2016113156A/ru not_active Application Discontinuation
- 2014-09-09 ES ES14843353.5T patent/ES2687598T3/es active Active
- 2014-09-09 CN CN201480049690.8A patent/CN105611923B/zh not_active Expired - Fee Related
- 2014-09-09 AU AU2014318979A patent/AU2014318979B2/en not_active Ceased
- 2014-09-09 MY MYPI2016700824A patent/MY181928A/en unknown
- 2014-09-09 JP JP2016540921A patent/JP6445565B2/ja active Active
- 2014-09-09 SG SG11201601367QA patent/SG11201601367QA/en unknown
- 2014-09-09 US US15/021,153 patent/US20160221974A1/en not_active Abandoned
- 2014-09-09 BR BR112016005271-4A patent/BR112016005271A2/pt not_active IP Right Cessation
-
2016
- 2016-01-13 US US14/994,846 patent/US9458118B2/en active Active
- 2016-02-12 PH PH12016500296A patent/PH12016500296A1/en unknown
- 2016-03-09 IL IL244506A patent/IL244506B/en active IP Right Grant
-
2017
- 2017-04-05 ZA ZA2017/02410A patent/ZA201702410B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3043787A4 (en) | 2017-02-01 |
| ZA201702410B (en) | 2019-06-26 |
| WO2015038533A2 (en) | 2015-03-19 |
| AU2014318979A1 (en) | 2016-03-03 |
| ES2687598T3 (es) | 2018-10-26 |
| SG10201805552PA (en) | 2018-08-30 |
| JP6445565B2 (ja) | 2018-12-26 |
| UA120353C2 (uk) | 2019-11-25 |
| US20160130239A1 (en) | 2016-05-12 |
| JP2016532716A (ja) | 2016-10-20 |
| KR20160054570A (ko) | 2016-05-16 |
| MX2016002881A (es) | 2016-04-21 |
| PH12016500296A1 (en) | 2016-05-16 |
| IL244506A0 (en) | 2016-04-21 |
| MY181928A (en) | 2021-01-14 |
| SG11201601367QA (en) | 2016-03-30 |
| AU2014318979B2 (en) | 2019-03-28 |
| CN105611923A (zh) | 2016-05-25 |
| RU2016113156A3 (OSRAM) | 2018-07-02 |
| BR112016005271A2 (pt) | 2020-05-12 |
| US9458118B2 (en) | 2016-10-04 |
| RU2016113156A (ru) | 2017-10-16 |
| US20160221974A1 (en) | 2016-08-04 |
| CN105611923B (zh) | 2019-08-23 |
| CA2922851C (en) | 2023-03-14 |
| EP3043787B1 (en) | 2018-09-05 |
| CA2922851A1 (en) | 2015-03-19 |
| EP3043787A2 (en) | 2016-07-20 |
| WO2015038533A3 (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201702410B (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| IL242564A0 (en) | Sodium channel modulators for pain management | |
| IL241026A0 (en) | A head device for treating and evaluating medical conditions | |
| HUE039560T2 (hu) | Mikro méretû zárófedés és kapcsolódó eljárások bõr kezelésére | |
| EP2967744A4 (en) | SKIN TREATMENT DEVICE | |
| PT2961269T (pt) | Dispositivo de depleção de gás para produtos sanguíneos | |
| PL2764881T3 (pl) | System leczenia medycznego | |
| IL238907A0 (en) | A device for treating depression, anxiety and pain | |
| EP2952149A4 (en) | THERAPEUTIC TREATMENT DEVICE | |
| SG11201509782TA (en) | Compositions and methods for the treatment of diabetes and pre-diabetes | |
| EP2867239A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | |
| EP3019138A4 (en) | Guiding means for administering acupuncture and other healing procedures | |
| GB201602663D0 (en) | Medical instrument and application thereof | |
| GB201315887D0 (en) | Medical applicator | |
| PL2986333T3 (pl) | Medyczny aplikator na skórę | |
| IL235272B (en) | Alfentanil preparation for the treatment of acute pain | |
| GB201309375D0 (en) | Medical methods and compounds for medical use | |
| EP3104869A4 (en) | Treatment of pain | |
| GB201316738D0 (en) | Implantable Medical Devices | |
| SG11201510081UA (en) | Surface modification of medical or veterinary devices | |
| LT2992094T (lt) | I tipo diabeto gydymo būdai ir kompozicijos | |
| GB201410954D0 (en) | Skin treatment devices and methods | |
| GB201309376D0 (en) | Medical methods and compounds for medical use | |
| GB201309498D0 (en) | Novel diagnosis and therapy | |
| AU2013905080A0 (en) | Treatment of Pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted |